NCT03470688 is a clinical trial of Originator in Rheumatoid Arthritis, sponsored by Opal Rheumatology Ltd..

Who is sponsoring NCT03470688?

NCT03470688 is sponsored by Opal Rheumatology Ltd..

What drugs are being tested in NCT03470688?

Interventions in NCT03470688: Originator, Biosimilar.

What condition does NCT03470688 study?

NCT03470688 studies Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis.

Is NCT03470688 still recruiting?

NCT03470688 is currently status unknown. Last updated 21 March 2018.

Last reviewed 2018-03-21 · How we verify

NCT03470688

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents

Status unknown Last updated 21 March 2018

What this trial tests

trial testing Originator in Rheumatoid Arthritis in 5,000 participants. Status unknown.

Timeline

1 March 2018

Primary endpoint
1 June 2021

31 December 2021

Quick facts

Lead sponsor	Opal Rheumatology Ltd.
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	5,000
Start date	1 March 2018
Primary completion	1 June 2021
Estimated completion	31 December 2021
Sites	22 locations across Australia

Drugs / interventions tested

Originator — full drug profile →
Biosimilar — full drug profile →

Conditions studied

Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →
Psoriatic Arthritis — all drugs for Psoriatic Arthritis →
Ankylosing Spondylitis — all drugs for Ankylosing Spondylitis →

Sponsor

Opal Rheumatology Ltd. — full company profile →

Who can join

18 and older, any sex, with Rheumatoid Arthritis or Psoriatic Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An observational study investigating the utilisation and effectiveness of originator and biosimilar anti-TNF agents in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Rheumatoid Arthritis

Currently open trials in the same condition.

NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03470688 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Opal Rheumatology Ltd.
Last refreshed: 21 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03470688.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing